Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Lifecare AS ( (DE:LFC0) ) just unveiled an update.
Lifecare ASA has reported promising early real-world results from its ongoing LFC-SEN-002 veterinary study, where its implantable continuous glucose monitoring technology is being tested in diabetic dogs. The first enrolled dog, treated at the Norwegian University of Life Sciences, showed improved glucose regulation and overall well-being after veterinarians used continuous glucose insight to optimize its diabetes management, underscoring the clinical value of frequent monitoring and clinician-led adjustments. These early findings support the relevance of CGM in veterinary diabetes care and validate Lifecare’s planned veterinary market pathway, while also generating in-vivo performance, biocompatibility and system stability data that feed directly into product optimization, de-risk future human clinical programs, and advance the company’s roadmap toward first-in-human studies and eventual CE marking.
More about Lifecare AS
Lifecare ASA is a Norwegian medical sensor company focused on developing next-generation continuous glucose monitoring (CGM) systems for humans and pets. Using osmotic pressure as its core sensing principle, the company aims to enable implantable sensors capable of detecting and monitoring a wide range of analytes and molecules, with a primary market focus on diabetes management.
YTD Price Performance: -34.86%
Average Trading Volume: 559,946
Current Market Cap: NOK162.1M
For detailed information about LFC0 stock, go to TipRanks’ Stock Analysis page.